08:09 AM EDT, 10/29/2024 (MT Newswires) -- Kiniksa Pharmaceuticals International (KNSA) reported a Q3 loss Tuesday of $0.18 per diluted share, narrower than a loss of $0.20 a year earlier.

Analysts surveyed by Capital IQ expected a profit of $0.10.

Revenue for the quarter ended Sept. 30 was $112.2 million, compared with $67 million a year earlier.

Analysts surveyed by Capital IQ expected $111.6 million.

The company expects 2024 Arcalyst net product revenue of between $410 million and $420 million, compared with the range of between $405 million and $415 million previously anticipated.